Results 51 to 60 of about 28,422 (269)

Pediatric severe asthma: A case series report and perspectives on anti-IgE treatment [PDF]

, 2018
Background The primary goal of asthma management is to achieve disease control for reducing the risk of future exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant morbidity.
Mirra, Virginia, Montella, Silvia, Santamaria, Francesca   +2 more
core   +1 more source

Omalizumab and Oral Immunotherapy in IgE-Mediated Food Allergy in Children: A Systematic Review and a Meta-Analysis

Pharmaceuticals
Background: Food allergies are a growing global health concern, particularly among children, with no widely approved curative treatment beyond strict allergen avoidance.
Enrico Buono, Giuliana Giannì, Sara Scavone, Susanna Esposito, Carlo Caffarelli   +4 more
semanticscholar   +1 more source

Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab [PDF]

, 2015
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated.
Gensbaur, Anna, Mempel, Martin, Mourantchanian, Vagkan, Ollert, Markus, Ring, Johannes, Seifert, Florian, Suarez, Isabel Leon, Weidinger, Stephan, Zink, Alexander, Zirbs, Michael   +9 more
core   +2 more sources

Omalizumab reduces anaphylactic reactions and allows food introduction in food‐allergic in children with severe asthma: An observational study

Allergy. European Journal of Allergy and Clinical Immunology
In Europe, Omalizumab (anti‐IgE) is indicated for the treatment of moderate to severe asthma, but not for IgE‐mediated food allergy (FA).
S. Arasi, Arianna Cafarotti, F. Galletta, Valentina Panetta, C. Riccardi, Veronica Calandrelli, V. Fierro, L. Dahdah, M. Artesani, R. Valluzzi, V. Pecora, Valeria Tallarico, G. Dinardo, Lucia Lo Scalzo, Alessandro G Fiocchi   +14 more
semanticscholar   +1 more source

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.

Journal of Allergy and Clinical Immunology, 2021
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently remains uncontrolled despite maximal medical therapy and sinonasal surgery, presenting several unmet needs and challenges.
P. Gevaert, R. Saenz, J. Corren, Joseph K. Han, J. Mullol, Stella E. Lee, R. Ow, R. Zhao, M. Howard, Kit Wong, L. Islam, M. Ligueros‐Saylan, T. Omachi, C. Bachert   +13 more
semanticscholar   +1 more source

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms

Journal of Clinical Investigation, 2022
Over the last 2 decades, omalizumab is the only anti-IgE antibody that has been approved for asthma and chronic spontaneous urticaria (CSU). Ligelizumab, a higher-affinity anti-IgE mAb and the only rival viable candidate in late-stage clinical trials ...
Be-Sheng Kuo, Chaoming Li, Jiun-Bo Chen, Yu-Yu Shiung, C. Chu, Chih-Hung Lee, Yaw-Jen Liu, J. Kuo, Cindy Hsu, Hsiao-Wen Su, Ywan-Feng Li, Annie Lai, Yueh-Feng Ho, Yi-Ning Cheng, Hong Huang, Meng-Chung Lung, M. Wu, Fuquan Yang, Chen-Han Lin, William Tseng, Jasper B. Yang, Chia-Yin Lin, Pei-hua Tsai, Heng-Kwei Chang, Yi-Jen Wang, Te-Chuan Chen, Shugene Lynn, M. Liao, Changcai Wang   +28 more
semanticscholar   +1 more source

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

Cancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna, Medina Esenbekova, Micheal Bishara, Layo Akinrinwoye, Joane Titus, Leila Metellus   +5 more
wiley   +1 more source

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Acta Dermato-Venereologica
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management ...
David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau   +6 more
doaj   +1 more source

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy, 2022
Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to European Union‐approved and United States‐licensed reference omalizumab (EU‐ and US‐omalizumab ...
Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan   +8 more
doaj   +1 more source

Dupilumab for bullous pemphigoid with intractable pruritus [PDF]

, 2019
Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z, Orme, Charisse M, Seidman, Jason S   +2 more
core